Therigy Debuts RSV Solution for TherigySTM

MAITLAND, Fla. - Nov. 10, 2014 - PRLog -- Therigy is pleased to announce the release of a new module, Respiratory Syncytial Virus (RSV), within its specialty therapy management application TherigySTM. Currently, Synagis® is the only FDA-approved drug commercially available in the United States for prevention of RSV infections, and TherigySTM’s new module for RSV delivers scripted assessments that follow approved clinical protocols and treatment guidelines for Synagis. TherigySTM for RSV also allows for standardized data capture that meets the contractual reporting requirements of MedImmune, the manufacturer of Synagis.

“We recognized that many pharmacies were struggling to standardize both the clinical care and data capture for Synagis patients,” said Russel Allinson, CEO and Chief Clinical Officer of Therigy. “This is a unique therapeutic category in that pharmacies often have to speak with both the providers and parents of babies receiving Synagis, which could create gaps in the collection of important clinical information.”

Recognizing the extensive reporting requirements for Synagis, Therigy enhanced its service offering to allow pharmacies to consolidate both prescription data captured within TherigySTM and dispensing data from the pharmacy’s dispensing system for one integrated data submission to MedImmune.  Pharmacies can choose to have TherigySTM submit these reports directly to MedImmune in the designated format and timeframe.

“We wanted to simplify a very complex process for pharmacies that dispense Synagis,” said Mr. Allinson. “By providing improved capacity to report contractually required data to MedImmune, we alleviate the very time-consuming administrative burden from pharmacy staff so they can focus on providing quality care for their Synagis patients.”

About TherigySTM

TherigySTM is a HIPAA-compliant, cloud-based application that delivers pre-configured disease and therapy-specific program content for specialty pharmacies to drive adherence and improve clinical outcomes for patients. “Ready-to-use,” scripted assessments integrate with leading pharmacy dispensing systems to manage all aspects of the patient’s therapy, including side effect management, recurring refill assessments, therapy discontinuation surveys, financial assistance information, patient support resources, clinical interventions, patient outcomes reports, and assessment scoring triggers. These automated care plans enable specialty pharmacies to effectively and efficiently manage, track, and report data on the treatment of patients on specialty medications.

A broad range of customers, including independent, vertically-integrated, and leading health system specialty pharmacies, use TherigySTM to support their operations.

About Therigy

Therigy is the trusted source for specialty solutions. We create leading web and mobile applications, provide consulting services, and deliver business intelligence for the specialty pharmaceutical market.  Clients leverage Therigy’s in-depth knowledge, extensive experience, and advanced products to achieve clinical and economic success by aligning strategy, technology, and people.